Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02626455




Registration number
NCT02626455
Ethics application status
Date submitted
3/11/2015
Date registered
10/12/2015

Titles & IDs
Public title
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Scientific title
A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Secondary ID [1] 0 0
2015-001088-38
Secondary ID [2] 0 0
17833
Universal Trial Number (UTN)
Trial acronym
CHRONOS-4
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lymphoma, Non-Hodgkin 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Copanlisib (BAY80-6946)
Treatment: Drugs - Placebo
Treatment: Drugs - Rituximab
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Doxorubicin
Treatment: Drugs - Vincristine
Treatment: Drugs - Bendamustine
Treatment: Drugs - Prednisone

Experimental: Copanlisib + R-B or R-CHOP / Arm 1 - Combination of copanlisib with standard immunochemotherapy (rituximab and bendamustine) \[R-B\] or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone \[R-CHOP\] (safety run-in and phase III)

Placebo comparator: Placebo + R-B or R-CHOP / Arm 2 - Combination of placebo and R-B or R-CHOP (phase III only)


Treatment: Drugs: Copanlisib (BAY80-6946)
Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.

Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days.

Treatment: Drugs: Placebo
Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.

Treatment: Drugs: Rituximab
Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.

Treatment: Drugs: Cyclophosphamide
Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP

Treatment: Drugs: Doxorubicin
Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP

Treatment: Drugs: Vincristine
Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP

Treatment: Drugs: Bendamustine
Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B

Treatment: Drugs: Prednisone
Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
SRI: Occurrence of Dose-limiting Toxicities (DLT)
Timepoint [1] 0 0
At Cycle 1: 28 days for Copa+R-B or 21 days for Copa+R-CHOP
Primary outcome [2] 0 0
Phase 3: Progression-free Survival (PFS) by Independent Central Review
Timepoint [2] 0 0
Approximately 6 years 4 months
Secondary outcome [1] 0 0
SRI: Best Overall Response
Timepoint [1] 0 0
Approximately 7 years 8 months
Secondary outcome [2] 0 0
SRI: Number of Subjects With Treatment-emergent Adverse Event (TEAE)
Timepoint [2] 0 0
Approximately 4 years 10 months
Secondary outcome [3] 0 0
Phase 3: Objective Tumor Response Rate (ORR)-Independent Central Review
Timepoint [3] 0 0
Up to 6 years 4 months
Secondary outcome [4] 0 0
Phase 3: ORR-Investigator Assessment
Timepoint [4] 0 0
Up to 6 years 4 months
Secondary outcome [5] 0 0
Phase 3: Duration of Tumor Response (DOR)-Independent Central Review
Timepoint [5] 0 0
Approximately 6 years 4 months
Secondary outcome [6] 0 0
Phase 3: DOR-Investigator Assessment
Timepoint [6] 0 0
Approximately 6 years 4 months
Secondary outcome [7] 0 0
Phase 3: Complete Tumor Response Rate (CRR)-Independent Central Review
Timepoint [7] 0 0
Approximately 6 years 4 months
Secondary outcome [8] 0 0
Phase 3: CRR-Investigator Assessment
Timepoint [8] 0 0
Approximately 6 years 4 months
Secondary outcome [9] 0 0
Phase 3: Disease Control Rate (DCR)-Independent Central Review
Timepoint [9] 0 0
Approximately 6 years 4 months
Secondary outcome [10] 0 0
Phase 3: DCR-Investigator Assessment
Timepoint [10] 0 0
Approximately 6 years 4 months
Secondary outcome [11] 0 0
Phase 3: Time to Tumor Progression (TTP)-Independent Central Review
Timepoint [11] 0 0
Approximately 6 years 4 months
Secondary outcome [12] 0 0
Phase 3: TTP-Investigator Assessment
Timepoint [12] 0 0
Approximately 6 years 4 months
Secondary outcome [13] 0 0
Phase 3: Time to Next Anti-lymphoma Treatment (TTNT)
Timepoint [13] 0 0
Approximately 6 years 4 months
Secondary outcome [14] 0 0
Phase 3: Overall Survival (OS)
Timepoint [14] 0 0
Approximately 6 years 4 months
Secondary outcome [15] 0 0
Phase 3: Time to Deterioration in Disease-related Symptoms-physical (DRS-P) of at Least 3 Points of Lymphoma
Timepoint [15] 0 0
Approximately 6 years 4 months
Secondary outcome [16] 0 0
Phase 3: Time to Improvement in Disease-related Symptoms-physical (DRS-P) of at Least 3 Points of Lymphoma
Timepoint [16] 0 0
Approximately 6 years 4 months
Secondary outcome [17] 0 0
Phase 3: Number of Subjects With Treatment-emergent Adverse Event (TEAE)
Timepoint [17] 0 0
Approximately 4 years

Eligibility
Key inclusion criteria
* Histologically confirmed diagnosis of B lymphocyte antigen CD20 positive iNHL with histological subtype limited to:

* Follicular lymphoma G1-2-3a
* Small lymphocytic lymphoma with absolute lymphocyte count <5x10E9/L at study entry
* Lymphoplasmacytoid lymphoma / Waldenström macroglobulinemia (LPL / WM)
* Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)
* Patients must have relapsed (recurrence after complete response or presented progression after partial response) or progressed after at least one but at most three prior lines of therapy, including rituximab, and/or rituximab biosimilars, and/or anti-CD20 monoclonal antibody (e.g. obinutuzumab) -based immunochemotherapy and alkylating agents (if given concomitantly is considered one line of therapy). A previous regimen is defined as one of the following: at least 2 months of single-agent therapy (less than 2 months of therapy with single agent rituximab, or rituximab biosimilars, or anti-CD20 monoclonal antibody can be considered a previous regimen in the case the patient responded to it); at least 2 consecutive cycles of polychemotherapy; autologous transplant; or radioimmunotherapy. Previous exposure to other PI3K Inhibitors (except copanlisib) is acceptable provided there is no resistance (resistance defined as no response (response defined as partial response [PR] or complete response [CR]) at any time during therapy, or progressive disease (PD) after any response (PR/CR) or after stable disease within 6 months from the end of the therapy with a PI3K inhibitor.
* Non-WM patients must have at least one bi-dimensionally measurable lesion (that has not been previously irradiated) according to the Lugano Classification. For patients with splenic MZL this requirement may be restricted to splenomegaly alone since that is usually the only manifestation of measurable disease.
* Patients affected by WM who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level = 2 x upper limit of normal and positive immunofixation test.
* Male or female patients = 18 years of age
* Eastern Cooperative Oncology Group (ECOG) performance status = 2
* Life expectancy of at least 3 months
* Availability of fresh tumor tissue and/or archival tumor tissue at Screening
* Adequate baseline laboratory values as assessed within 7 days before starting study treatment.
* Left ventricular ejection fraction = 50%
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Histologically confirmed diagnosis of follicular lymphoma grade 3b or transformed disease, or chronic lymphocytic leukemia. In patients with clinical suspicion of transformed disease, a fresh biopsy is recommended.
* Rituximab, or rituximab biosimilars, or anti-CD20 monoclonal antibody (e.g. obinutuzumab) resistance at any line of therapy (resistance defined as lack of response, or progression within 6 months of the last date of rituximab, or rituximab biosimilars, or anti-CD20 monoclonal antibody administration, including maintenance with these drugs).
* HbA1c > 8.5% at screening
* History or concurrent condition of interstitial lung disease and/or severely impaired lung function (as judged by the investigator)
* Known lymphomatous involvement of the central nervous system
* Known history of human immunodeficiency virus (HIV) infection
* Hepatitis B (HBV) or hepatitis C (HCV) infection. Patients positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) will be eligible if they are negative for HBV-DNA, these patients should receive prophylactic antiviral therapy as per rituximab label. Patients positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA.
* Cytomegalovirus (CMV) infection. Patients who are CMV PCR positive at baseline will not be eligible.CMV PCR test is considered positive if, the result can be interpreted as a CMV viremia according to local standard of care.
* Uncontrolled hypertension despite optimal medical management (per investigator´s assessment)
* Congestive heart failure > New York Heart Association (NYHA) class 2

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/01/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/11/2023
Sample size
Target
Accrual to date
Final
551
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Calvary Mater Hospital Newcastle - Waratah
Recruitment hospital [2] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [3] 0 0
Ashford Cancer Centre Research Pty Ltd - Kurralta Park
Recruitment hospital [4] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [5] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [6] 0 0
Eastern Health Integrated Renal Service - Box Hill
Recruitment postcode(s) [1] 0 0
2298 - Waratah
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment postcode(s) [5] 0 0
6961 - Murdoch
Recruitment postcode(s) [6] 0 0
3128 - Box Hill
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
Belgium
State/province [8] 0 0
Bruxelles
Country [9] 0 0
Belgium
State/province [9] 0 0
Gent
Country [10] 0 0
Belgium
State/province [10] 0 0
Leuven
Country [11] 0 0
Belgium
State/province [11] 0 0
Liege
Country [12] 0 0
Brazil
State/province [12] 0 0
Parana
Country [13] 0 0
Brazil
State/province [13] 0 0
Rio Grande Do Sul
Country [14] 0 0
Brazil
State/province [14] 0 0
Santa Catarina
Country [15] 0 0
Brazil
State/province [15] 0 0
Sao Paulo
Country [16] 0 0
Brazil
State/province [16] 0 0
Rio de Janeiro
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Plovdiv
Country [18] 0 0
Bulgaria
State/province [18] 0 0
Sofia
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Vratsa
Country [20] 0 0
Canada
State/province [20] 0 0
Quebec
Country [21] 0 0
Chile
State/province [21] 0 0
Araucanía
Country [22] 0 0
Chile
State/province [22] 0 0
Valparaíso
Country [23] 0 0
Chile
State/province [23] 0 0
Santiago
Country [24] 0 0
China
State/province [24] 0 0
Fujian
Country [25] 0 0
China
State/province [25] 0 0
Guangdong
Country [26] 0 0
China
State/province [26] 0 0
Hebei
Country [27] 0 0
China
State/province [27] 0 0
Henan
Country [28] 0 0
China
State/province [28] 0 0
Jiangsu
Country [29] 0 0
China
State/province [29] 0 0
Jilin
Country [30] 0 0
China
State/province [30] 0 0
Shandong
Country [31] 0 0
China
State/province [31] 0 0
Sichuan
Country [32] 0 0
China
State/province [32] 0 0
Zhejiang
Country [33] 0 0
China
State/province [33] 0 0
Beijing
Country [34] 0 0
China
State/province [34] 0 0
Shanghai
Country [35] 0 0
China
State/province [35] 0 0
Tianjin
Country [36] 0 0
Czechia
State/province [36] 0 0
Hradec Kralove
Country [37] 0 0
Czechia
State/province [37] 0 0
Praha 10
Country [38] 0 0
Denmark
State/province [38] 0 0
København Ø
Country [39] 0 0
Denmark
State/province [39] 0 0
Odense C
Country [40] 0 0
Finland
State/province [40] 0 0
Helsinki
Country [41] 0 0
Finland
State/province [41] 0 0
Oulu
Country [42] 0 0
Finland
State/province [42] 0 0
Tampere
Country [43] 0 0
Finland
State/province [43] 0 0
Turku
Country [44] 0 0
France
State/province [44] 0 0
Angers
Country [45] 0 0
France
State/province [45] 0 0
Avignon
Country [46] 0 0
France
State/province [46] 0 0
Bayonne
Country [47] 0 0
France
State/province [47] 0 0
Grenoble
Country [48] 0 0
France
State/province [48] 0 0
Le Mans Cedex 2
Country [49] 0 0
France
State/province [49] 0 0
Limoges Cedex
Country [50] 0 0
France
State/province [50] 0 0
Montpellier Cedex
Country [51] 0 0
France
State/province [51] 0 0
Nantes
Country [52] 0 0
France
State/province [52] 0 0
Paris
Country [53] 0 0
France
State/province [53] 0 0
Pessac
Country [54] 0 0
France
State/province [54] 0 0
Poitiers
Country [55] 0 0
France
State/province [55] 0 0
Strasbourg
Country [56] 0 0
Germany
State/province [56] 0 0
Baden-Württemberg
Country [57] 0 0
Germany
State/province [57] 0 0
Bayern
Country [58] 0 0
Germany
State/province [58] 0 0
Niedersachsen
Country [59] 0 0
Germany
State/province [59] 0 0
Nordrhein-Westfalen
Country [60] 0 0
Germany
State/province [60] 0 0
NRW
Country [61] 0 0
Germany
State/province [61] 0 0
Sachsen-Anhalt
Country [62] 0 0
Greece
State/province [62] 0 0
Athens
Country [63] 0 0
Greece
State/province [63] 0 0
Chaidari
Country [64] 0 0
Greece
State/province [64] 0 0
Larissa
Country [65] 0 0
Greece
State/province [65] 0 0
Patras
Country [66] 0 0
Hong Kong
State/province [66] 0 0
Hong Kong
Country [67] 0 0
Hungary
State/province [67] 0 0
Budapest
Country [68] 0 0
Hungary
State/province [68] 0 0
Kaposvar
Country [69] 0 0
Hungary
State/province [69] 0 0
Nyiregyhaza
Country [70] 0 0
Hungary
State/province [70] 0 0
Pecs
Country [71] 0 0
Hungary
State/province [71] 0 0
Tatabanya
Country [72] 0 0
Ireland
State/province [72] 0 0
Cork
Country [73] 0 0
Ireland
State/province [73] 0 0
Dublin
Country [74] 0 0
Israel
State/province [74] 0 0
Haifa
Country [75] 0 0
Israel
State/province [75] 0 0
Jerusalem
Country [76] 0 0
Israel
State/province [76] 0 0
Ramat Gan
Country [77] 0 0
Israel
State/province [77] 0 0
Zerifin
Country [78] 0 0
Italy
State/province [78] 0 0
Liguria
Country [79] 0 0
Italy
State/province [79] 0 0
Lombardia
Country [80] 0 0
Italy
State/province [80] 0 0
Marche
Country [81] 0 0
Japan
State/province [81] 0 0
Aichi
Country [82] 0 0
Japan
State/province [82] 0 0
Fukuoka
Country [83] 0 0
Japan
State/province [83] 0 0
Gunma
Country [84] 0 0
Japan
State/province [84] 0 0
Hyogo
Country [85] 0 0
Japan
State/province [85] 0 0
Kanagawa
Country [86] 0 0
Japan
State/province [86] 0 0
Miyagi
Country [87] 0 0
Japan
State/province [87] 0 0
Nara
Country [88] 0 0
Japan
State/province [88] 0 0
Osaka
Country [89] 0 0
Japan
State/province [89] 0 0
Saitama
Country [90] 0 0
Japan
State/province [90] 0 0
Tokyo
Country [91] 0 0
Japan
State/province [91] 0 0
Aomori
Country [92] 0 0
Japan
State/province [92] 0 0
Hiroshima
Country [93] 0 0
Japan
State/province [93] 0 0
Kumamoto
Country [94] 0 0
Japan
State/province [94] 0 0
Yamagata
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Seoul Teugbyeolsi
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Seoul
Country [97] 0 0
Mexico
State/province [97] 0 0
Distrito Federal
Country [98] 0 0
Mexico
State/province [98] 0 0
Michoacán
Country [99] 0 0
Mexico
State/province [99] 0 0
Nuevo Leon
Country [100] 0 0
Mexico
State/province [100] 0 0
Veracruz
Country [101] 0 0
Mexico
State/province [101] 0 0
Yucatán
Country [102] 0 0
Poland
State/province [102] 0 0
Gdynia
Country [103] 0 0
Poland
State/province [103] 0 0
Krakow
Country [104] 0 0
Poland
State/province [104] 0 0
Lodz
Country [105] 0 0
Portugal
State/province [105] 0 0
Braga
Country [106] 0 0
Portugal
State/province [106] 0 0
Porto
Country [107] 0 0
Romania
State/province [107] 0 0
Baia Mare
Country [108] 0 0
Romania
State/province [108] 0 0
Brasov
Country [109] 0 0
Romania
State/province [109] 0 0
Bucuresti
Country [110] 0 0
Romania
State/province [110] 0 0
Craiova
Country [111] 0 0
Romania
State/province [111] 0 0
Iasi
Country [112] 0 0
Romania
State/province [112] 0 0
Sibiu
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Kemerovo
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Omsk
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Rostov-on-Don
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Saint-Petersburg
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Sochi
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Tomsk
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Ufa
Country [120] 0 0
Singapore
State/province [120] 0 0
Singapore
Country [121] 0 0
Slovakia
State/province [121] 0 0
Bratislava
Country [122] 0 0
South Africa
State/province [122] 0 0
Eastern Cape
Country [123] 0 0
South Africa
State/province [123] 0 0
Gauteng
Country [124] 0 0
South Africa
State/province [124] 0 0
Western Cape
Country [125] 0 0
Spain
State/province [125] 0 0
Barcelona
Country [126] 0 0
Spain
State/province [126] 0 0
Madrid
Country [127] 0 0
Spain
State/province [127] 0 0
Málaga
Country [128] 0 0
Spain
State/province [128] 0 0
Zaragoza
Country [129] 0 0
Taiwan
State/province [129] 0 0
Changhua
Country [130] 0 0
Taiwan
State/province [130] 0 0
Kaohsiung
Country [131] 0 0
Taiwan
State/province [131] 0 0
Tainan
Country [132] 0 0
Taiwan
State/province [132] 0 0
Taipei
Country [133] 0 0
Thailand
State/province [133] 0 0
Bangkok
Country [134] 0 0
Turkey
State/province [134] 0 0
Ankara
Country [135] 0 0
Turkey
State/province [135] 0 0
Edirne
Country [136] 0 0
Turkey
State/province [136] 0 0
Istanbul
Country [137] 0 0
Turkey
State/province [137] 0 0
Izmir
Country [138] 0 0
Turkey
State/province [138] 0 0
Kayseri
Country [139] 0 0
Turkey
State/province [139] 0 0
Samsun
Country [140] 0 0
Turkey
State/province [140] 0 0
Trabzon
Country [141] 0 0
Ukraine
State/province [141] 0 0
Cherkasy
Country [142] 0 0
Ukraine
State/province [142] 0 0
Dnipro
Country [143] 0 0
Ukraine
State/province [143] 0 0
Kyiv
Country [144] 0 0
Ukraine
State/province [144] 0 0
Lviv
Country [145] 0 0
Ukraine
State/province [145] 0 0
Zaporizhzhya
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Devon
Country [147] 0 0
United Kingdom
State/province [147] 0 0
London
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Dorchester
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT02626455